

Contact Person: Wilna Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 622B, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7410, Telephone: 301/496-7903.

Purpose/Agenda: To evaluate and review responses to Request for Proposal.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: July 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, National Institute of Health.

[FR Doc. 97-20857 Filed 8-6-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Closed Meeting of the National Deafness and Other Communication Disorders Advisory Council

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Deafness and Other Communication Disorders Advisory Council from 1-2 pm on September 11, 1997, in Building 31, Room 3C05, National Institutes of Health, 9000 Rockville Pike, Bethesda MD 20892. The meeting will be held as a telephone conference call.

In accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, United States Code and section 10(d) of Pub. L. 92-463, the meeting will be closed to the public. The meeting will include the review, discussion, evaluation of individual grant applications. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning

individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Further information concerning the meeting may be obtained from Dr. Craig A. Jordan, Executive Secretary, National Deafness and Other Communication Disorders Advisory Council National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Executive Plaza South, Room 400C, 6120 Executive Blvd., MSC7180, Bethesda, Maryland 20892-7180, (301) 496-8693. A summary of the meeting and rosters of the members may also be obtained from his office.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: July 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, National Institutes of Health.

[FR Doc. 97-20858 Filed 8-6-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the following National Heart, Lung, and Blood Institute Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: Clinical Trials in Diabetes and CVD.

Date: September 19, 1997.

Time: 8:00 a.m.

Place: NIH Main Campus, 31 Center Drive, Building 31, 6th Floor, C Wing, Conference Room 7.

Agenda: To consider the need for a clinical trial to determine optimal intervention strategies to prevent or reduce CVD in diabetic patients.

Contact Persons:

Peter Savage, M.D., Deputy Director, DECA, II Rockledge Center, 6701 Rockledge Drive, MSC 7938, Room 8104, Bethesda, Maryland 20892-7938, (301) 435-0422.
George Sopko, M.D., Medical Officer, DHVD, II Rockledge Center, 6701 Rockledge Drive,

MSC 7940, Room 9176, Bethesda, MD 20892-7940, (301) 435-0515.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: July 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-20864 Filed 8-6-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the following National Heart, Lung, and Blood Institute Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: New Approaches to Complex Biological Problems: Inflammation and Risk Assessment.

Date: September 19, 1997.

Time: 8:00 a.m.

Place: Two Rockledge Center, 6701 Rockledge Drive, Room 7111, Bethesda, Maryland 20892.

Agenda: To consider the approach and need for additional research to improve understanding of the pathogenesis of inflammation in the lung and clinical risk assessment related to it by use of non-linear mathematical techniques.

Contact Person: Hannah H. Peavy, M.D., NHLBI/DLD Lung Biology and Disease Program, Two Rockledge Center, Room 10110, 6701 Rockledge Drive, MSC 7952, Bethesda, Maryland 20892, (301) 435-0222. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: July 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97-20865 Filed 8-6-97; 8:45 am]

BILLING CODE 4140-01-M